ArticleScientific reports2026
Hypertension prevalence and control in selected townships of Lingcheng District, Dezhou City, China: a cross-sectional study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Despite the increasing prevalence of hypertension (HTN) in China, the rates of treatment and control remain uncertain. This study aims to evaluate the prevalence, awareness, treatment, and control rates of HTN in selected townships. From May 1, 2024, to July 31, 2024, a random sampling survey was conducted involving 11,600 adult residents across seven community health service centers in Lingcheng District, Dezhou City, Shandong Province, China. Following a standardized rest period of 5 to 10 min, trained healthcare professionals measured blood pressure using a validated oscillometric monitor. According to the 2024 Chinese guidelines for HTN, HTN is defined as a systolic blood pressure (SBP) of ≥ 140 mmHg or a diastolic blood pressure (DBP) of ≥ 90 mmHg, as well as individuals with a self-reported history of HTN who are currently taking antihypertensive medication. Normal-high blood pressure (NHBP) is characterized by an SBP of 120 to 139 mmHg or a DBP of 80 to 89 mmHg in the absence of antihypertensive medication. HTN control is defined as blood pressure readings of < 140/90 mmHg. Additionally, the prevalence and control rate of HTN were estimated using a cutoff of 130/80 mmHg, in accordance with the 2025 American Heart Association/American College of Cardiology High Blood Pressure Guideline. The age-adjusted prevalence of HTN was 32.2%, while the age-adjusted prevalence of NHBP was 30.9%. Among patients diagnosed with HTN, the age-adjusted awareness rate was 57.4%, the treatment rate was 50.0%, and the control rate was 38.0%. Of those receiving treatment, 56.1% were prescribed a single antihypertensive medication, 31.7% required a combination of two drugs, and 12.2% needed three or more antihypertensive medications. According to the 2025 American Heart Association/American College of Cardiology guideline, the age-adjusted prevalence of HTN was 57.3%, with a control rate of only 14.7%. This cross-sectional study indicated a high prevalence of HTN in selected townships of Lingcheng District. Although the awareness, treatment, and control rates of HTN have improved, they remain significantly below the desired levels. This finding underscores the substantial challenges associated with HTN management at the grassroots level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.